相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Clinical Implications of KEAP1-NFE2L2 Mutations in NSCLC
Jessica A. Hellyer et al.
JOURNAL OF THORACIC ONCOLOGY (2021)
PDL1 high expression without TP53, KEAP1 and EPHA5 mutations could better predict survival for patients with NSCLC receiving atezolizumab
Haiyong Wang et al.
LUNG CANCER (2021)
Divulging the Intricacies of Crosstalk Between NF-Kb and Nrf2-Keap1 Pathway in Neurological Complications of COVID-19
Ranjana Bhandari et al.
MOLECULAR NEUROBIOLOGY (2021)
Survival analysis for non-squamous NSCLC patients harbored STK11 or KEAP1 mutation receiving atezolizumab
Xiaoling Shang et al.
LUNG CANCER (2021)
Role of KEAP1/NFE2L2 Mutations in the Chemotherapeutic Response of Patients with Non-Small Cell Lung Cancer
Youngtae Jeong et al.
CLINICAL CANCER RESEARCH (2020)
NOX4 Inhibition Potentiates Immunotherapy by Overcoming Cancer-Associated Fibroblast-Mediated CD8 T-cell Exclusion from Tumors
Kirsty Ford et al.
CANCER RESEARCH (2020)
Tumor-associated macrophages secrete CC-chemokine ligand 2 and induce tamoxifen resistance by activating PI3K/Akt/mTOR in breast cancer
Dongbo Li et al.
CANCER SCIENCE (2020)
Beyond repression of Nrf2: An update on Keap1
Aleksandra Kopacz et al.
FREE RADICAL BIOLOGY AND MEDICINE (2020)
KEAP1/NFE2L2 as a prognostic biomarker on immunotherapy and correlation with immune infiltrates in non-small cell lung cancer (NSCLC).
Hongyuan Zhu et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Keap1-Nrf2 signaling pathway in angiogenesis and vascular diseases
Zi Guo et al.
JOURNAL OF TISSUE ENGINEERING AND REGENERATIVE MEDICINE (2020)
The Molecular Mechanisms Regulating the KEAP1-NRF2 Pathway
Liam Baird et al.
MOLECULAR AND CELLULAR BIOLOGY (2020)
NFE2L2/KEAP1 Mutations Correlate with Higher Tumor Mutational Burden Value/PD-L1 Expression and Potentiate Improved Clinical Outcome with Immunotherapy
Xian Xu et al.
ONCOLOGIST (2020)
KEAP1-driven co-mutations in lung adenocarcinoma unresponsive to immunotherapy despite high tumor mutational burden
D. Marinelli et al.
ANNALS OF ONCOLOGY (2020)
KEAP1-NFE2L2-Mutant NSCLC and Immune Checkpoint Inhibitors: A Large Database Analysis
Chenyue Zhang et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
Can Activation of NRF2 Be a Strategy COVID-19?
Antonio Cuadrado et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2020)
Keap1 inhibition sensitizes head and neck squamous cell carcinoma cells to ionizing radiation via impaired non-homologous end joining and induced autophagy
Sara Sofia Deville et al.
CELL DEATH & DISEASE (2020)
KEAP1/NFE2L2 Mutations Predict Lung Cancer Radiation Resistance That Can Be Targeted by Glutaminase Inhibition
Michael S. Binkley et al.
CANCER DISCOVERY (2020)
Relationship between STK11 and KEAP1 mutational status and efficacy in KEYNOTE-042: pembrolizumab monotherapy versus platinum-based chemotherapy as first-line therapy for PD-L1-positive advanced NSCLC
Byoung Chul Cho et al.
CANCER RESEARCH (2020)
LKB1 and KEAP1/NRF2 Pathways Cooperatively Promote Metabolic Reprogramming with Enhanced Glutamine Dependence in KRAS-Mutant Lung Adenocarcinoma
Ana Galan-Cobo et al.
CANCER RESEARCH (2019)
Pharmacological Applications of Nrf2 Inhibitors as Potential Antineoplastic Drugs
Pelin Telkoparan-Akillilar et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Association of STK11/LKB1 genomic alterations with lack of benefit from the addition of pembrolizumab to platinum doublet chemotherapy in non-squamous non-small cell lung cancer.
Ferdinandos Skoulidis et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Impact of KEAP1/NFE2L2/CUL3 mutations on duration of response to EGFR tyrosine kinase inhibitors in EGFR mutated non-small cell lung cancer
Jessica A. Hellyer et al.
LUNG CANCER (2019)
Mutations in the KEAP1-NFE2L2 Pathway Define a Molecular Subset of Rapidly Progressing Lung Adenocarcinoma
Frauke Goeman et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Activators and Inhibitors of NRF2: A Review of Their Potential for Clinical Development
Natalia Robledinos-Anton et al.
OXIDATIVE MEDICINE AND CELLULAR LONGEVITY (2019)
CPUY192018, a potent inhibitor of the Keap1-Nrf2 protein-protein interaction, alleviates renal inflammation in mice by restricting oxidative stress and NF-κB activation
Meng-Chen Lu et al.
REDOX BIOLOGY (2019)
Mutations in the Antioxidant KEAP1/NRF2 Pathway Define an Aggressive Subset of NSCLC Resistant to Conventional Treatments
Ernest Nadal et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Mutations Associated with Sensitivity or Resistance to Immunotherapy in mNSCLC: Analysis from the MYSTIC Trial
N. Rizvi et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Targeting the cell signaling pathway Keap1-Nrf2 as a therapeutic strategy for adenocarcinomas of the lung
Bo Zhang et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2019)
Activation of c-Met in cancer cells mediates growth-promoting signals against oxidative stress through Nrf2-HO-1
Samik Chakraborty et al.
ONCOGENESIS (2019)
mTOR-Mediated Antioxidant Activation in Solid Tumor Radioresistance
Yunseo Woo et al.
JOURNAL OF ONCOLOGY (2019)
NRF2 and the Hallmarks of Cancer
Montserrat Rojo de la Vega et al.
CANCER CELL (2018)
ClinicalandPathological Characteristics of KEAP1- and NFE2L2-Mutated Non-Small Cell Lung Carcinoma (NSCLC)
Rieke Frank et al.
CLINICAL CANCER RESEARCH (2018)
THE KEAP1-NRF2 SYSTEM: A THIOL-BASED SENSOR-EFFECTOR APPARATUS FOR MAINTAINING REDOX HOMEOSTASIS
Masayuki Yamamoto et al.
PHYSIOLOGICAL REVIEWS (2018)
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
Sanjeev Mariathasan et al.
NATURE (2018)
Design and development of Nrf2 modulators for cancer chemoprevention and therapy: a review
Matej Sova et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2018)
Role of KEAP1/NRF2 and TP53 Mutations in Lung Squamous Cell Carcinoma Development and Radiation Resistance
Youngtae Jeong et al.
CANCER DISCOVERY (2017)
ATM, ATR, and DNA-PK: The Trinity at the Heart of the DNA Damage Response
Andrew N. Blackford et al.
MOLECULAR CELL (2017)
Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis
Rodrigo Romero et al.
NATURE MEDICINE (2017)
Oxidative Stress
Helmut Sies et al.
ANNUAL REVIEW OF BIOCHEMISTRY, VOL 86 (2017)
Small Molecule Inhibitor of NRF2 Selectively Intervenes Therapeutic Resistance in KEAP1-Deficient NSCLC Tumors
Anju Singh et al.
ACS CHEMICAL BIOLOGY (2016)
Functional crosstalk between DNA damage response proteins 53BP1 and BRCA1 regulates double strand break repair choice
Ali Bakr et al.
RADIOTHERAPY AND ONCOLOGY (2016)
TrxR1 as a Potent Regulator of the Nrf2-Keap1 Response System
Marcus Cebula et al.
ANTIOXIDANTS & REDOX SIGNALING (2015)
Novel Roles of c-Met in the Survival of Renal Cancer Cells through the Regulation of HO-1 and PD-L1 Expression
Murugabaskar Balan et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2015)
Hrd1 suppresses Nrf2-mediated cellular protection during liver cirrhosis
Tongde Wu et al.
GENES & DEVELOPMENT (2014)
Phosphorylation of p62 Activates the Keap1-Nrf2 Pathway during Selective Autophagy
Yoshinobu Ichimura et al.
MOLECULAR CELL (2013)
Modulation of oxidative stress as an anticancer strategy
Chiara Gorrini et al.
NATURE REVIEWS DRUG DISCOVERY (2013)
Regulatory flexibility in the Nrf2-mediated stress response is conferred by conformational cycling of the Keap1-Nrf2 protein complex
Liam Baird et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Accumulation of p62/SQSTM1 is associated with poor prognosis in patients with lung adenocarcinoma
Daisuke Inoue et al.
CANCER SCIENCE (2012)
Playing the End Game: DNA Double-Strand Break Repair Pathway Choice
J. Ross Chapman et al.
MOLECULAR CELL (2012)
Comprehensive genomic characterization of squamous cell lung cancers
Peter S. Hammerman et al.
NATURE (2012)
The Role of NF-E2-Related Factor 2 in Predicting Chemoresistance and Prognosis in Advanced Non-Small-Cell Lung Cancer
Haihong Yang et al.
CLINICAL LUNG CANCER (2011)
SCF/β-TrCP Promotes Glycogen Synthase Kinase 3-Dependent Degradation of the Nrf2 Transcription Factor in a Keap1-Independent Manner
Patricia Rada et al.
MOLECULAR AND CELLULAR BIOLOGY (2011)
Heme Oxygenase-1 in Tumor Biology and Therapy
Halina Was et al.
CURRENT DRUG TARGETS (2010)
Global mapping of binding sites for Nrf2 identifies novel targets in cell survival response through ChIP-Seq profiling and network analysis
Deepti Malhotra et al.
NUCLEIC ACIDS RESEARCH (2010)
Neurodegenerative diseases and oxidative stress
KJ Barnham et al.
NATURE REVIEWS DRUG DISCOVERY (2004)
Identification of the interactive interface and phylogenic conservation of the Nrf2-Keap1 system
M Kobayashi et al.
GENES TO CELLS (2002)
分享论文
